ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pemigatinib

Also written as “Pemigatinib”.

Its studies are mostly in Cholangiocarcinoma · Carcinoma, Transitional Cell · Glioblastoma · Neoplasms, Unknown Primary · Myeloproliferative Disorders, led by 3 companies.

Drug pagePemigatinib: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 29, 201816 company-led studies, 1 open or runningNext primary completion: Feb 25, 2031 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte131 open or runningphase 3since Aug 29, 2018Jan 30, 2015Feb 25, 2031phase 2 · NCT07862998
Innovent Biologicsits history only20 open or runningphase 2since Jan 20, 2020Jan 20, 2020none ahead
Hoffmann-La Rocheits history only10 open or runningphase 2since Apr 5, 2018Apr 5, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Incyte only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 30, 2015First study: phase 2 study in Lung NeoplasmsFirst studyNCT02393248 · 201 enrolled · United States, Denmark
  2. Aug 16, 2016Phase 2 study in Carcinoma, Transitional CellNCT02872714 · 263 enrolled · United States, Belgium, Denmark and more
  3. Oct 4, 2016Phase 2 study in CholangiocarcinomaNCT02924376 · 147 enrolled · United States, Belgium, France and more
  4. Jan 4, 2017Phase 2 study in Myeloproliferative DisordersNCT03011372 · 47 enrolled · United States, Austria, Belgium and more
  5. Jul 27, 2017Phase 1 study in NeoplasmsNCT03235570 · 44 enrolled · Japan
  6. Dec 9, 2017Named pemigatinibINNProposed as its International Nonproprietary Name in WHO's List 118
  7. Aug 29, 2018Phase 3 study in CholangiocarcinomaNCT03656536 · 167 enrolled · United States, Austria, Belgium and more
  8. Jan 28, 2019Phase 2 study in AcrocephalosyndactyliaNCT03822117 · 111 enrolled · United States, Denmark, France and more
  9. Jun 25, 20192 phase 2 studiesNCT04003623, NCT04003610
  10. Jun 25, 2021Phase 2 study in Advanced MalignanciesNCT04949191 · 10 enrolled · United States, Denmark, Italy and more
  11. Feb 14, 20222 phase 2 studiesNCT05253807, NCT05267106
  12. Oct 2, 2026Phase 2 study in CholangiocarcinomaNCT07862998 · 72 planned

Ahead

  1. Feb 25, 2031Primary completion: phase 2 study in CholangiocarcinomaNCT07862998

TargetBeta

“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), ”NCIt, by rule
“Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
infigratinibruleBridgeBiophase 317
futibatinibruleOtsukaphase 310

Studies

All 13 Incyte leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07862998Cholangiocarcinoma2Not yet recruitingFeb 25, 203172
NCT05267106Glioblastoma · United States, Denmark, France and more2TerminatedDec 17, 202483
NCT05253807Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more2CompletedAug 16, 20238
NCT04949191Advanced Malignancies · United States, Denmark, Italy and more2TerminatedApr 11, 202410
NCT04003610Carcinoma, Transitional Cell · United States, Austria, Belgium and more2TerminatedApr 18, 20217
NCT04003623Neoplasm Metastasis · United States2TerminatedJun 12, 20201
NCT03822117Acrocephalosyndactylia · United States, Denmark, France and more2TerminatedMar 29, 2022111
NCT03656536Cholangiocarcinoma · United States, Austria, Belgium and more3TerminatedJul 7, 2025167
NCT03235570Neoplasms · Japan1CompletedMar 4, 202044
NCT03011372Myeloproliferative Disorders · United States, Austria, Belgium and more2CompletedOct 30, 202447
NCT02924376Cholangiocarcinoma · United States, Belgium, France and more2CompletedFeb 1, 2022147
NCT02872714Carcinoma, Transitional Cell · United States, Belgium, Denmark and more2CompletedFeb 1, 2022263
NCT02393248Lung Neoplasms · United States, Denmark2TerminatedDec 17, 2021201

How it is read

Names in the registry

  • “Pemigatinib”, 15 entries
  • “pemigatinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.